Conditions: Hepatitis C
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 9
Healthy volunteers: no

Brief summary:
This adaptive design study will evaluate the safety, pharmacokinetics, and effect on hepatitis C virus (HCV) RNA levels of multiple doses of MK-8876 in participants with HCV infection. The study will consist of 4 parts evaluating participants infected with specific hepatitis C virus genotypes and up to 10 panels allowing for additional participants to enroll in each panel as specified in the study analysis. The hypothesis evaluated in the study is that a ≥2.5 log IU/mL reduction in HCV RNA from Baseline will accompany multiple dose administration of MK-8876 in participants with HCV infection.

Detailed description:

Arms:
arm 1: Participants infected with HCV GT3 received 150 mg MK-8876 once daily (q.d.) by mouth for 7 days. arm 2: Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days. arm 3: Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.

Interventions: intervention 1: MK-8876
Intervention descriptions: intervention 1: MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.

Protocol document: